Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Itakura

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 13, 2018
Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infectionYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
International Journal of Molecular Sciences|December 30, 2020
<i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health CheckupNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovirNobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|August 31, 2023
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis BShun Ishido, Nobuharu Tamaki, Naoki Uchihara, et al.
Plos One|August 16, 2016
Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular CarcinomaYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
Journal of Medical Virology|January 30, 2020
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis BNobuharu Tamaki, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Cancers|August 30, 2019
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular CarcinomaHitomi Takada, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Clinical Case Reports|July 7, 2023
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling testShun Ishido, Nobuharu Tamaki, Kento Inada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2021
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin gradeShun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 13, 2018
Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infectionYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
International Journal of Molecular Sciences|December 30, 2020
<i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health CheckupNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovirNobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|August 31, 2023
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis BShun Ishido, Nobuharu Tamaki, Naoki Uchihara, et al.
Plos One|August 16, 2016
Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular CarcinomaYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
Journal of Medical Virology|January 30, 2020
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis BNobuharu Tamaki, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Cancers|August 30, 2019
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular CarcinomaHitomi Takada, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Clinical Case Reports|July 7, 2023
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling testShun Ishido, Nobuharu Tamaki, Kento Inada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2021
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin gradeShun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Pageof 13